Business
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023
SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new
About this update from Sanuwave Health, Inc.
[{"type":"text","content":"SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company.\nQ4 2023 revenue increased 20% to 24% over Q4 2022 and in excess of 30% versus the third quarter of 2023.\nPreliminary FY 2023 revenue range was $20.0 million to $20.2 million, an increase of 19% to 20% year over year. This represents record annual revenues for the Company.\nUltraMist revenues for Q4 2023 increased by more than 30% versus Q3 2023 and accounted for approximately 95% of the Company's total revenues.\nEDEN PRAIRIE, MN - (NewMediaWire) - January 10, 2024 - SANUWAVE Health, Inc. (the \"Company\" or \"SANUWAVE\") (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the fourth quarter of 2023 are expected to be in the range of $6.6 to $6.8 million, an increase of 20% to 24% over Q4 2022. Fiscal year 2023 revenues are expected to be in the range of $20.0 million to $20.2 million, an increase of 19% to 20% over the fiscal year ended 2022.\n\"Q4 2023 was a record quarter of revenue for SANUWAVE driven by strength in the UltraMist product line. Consumables and in particular system sales saw accelerating growth as production constraints were overcome,\" said CEO Morgan Frank. \"We're extremely pleased to have shown this level of growth year on year up against what had previously been the best quarter in SANUWAVE history in Q4 2022 and look forward to carrying this success on into 2024. The Company plans to release its full Q4 and annual results in late March and we look forward to speaking with you then to give you a more complete update on our quarterly and yearly performance and our future plans and guidance.\"\nThe preliminary revenue results described herein are based on management's initial analysis of the fourth quarter ended December 31, 2023, and may be subject to adjustments based on the Company's completion of its year-end financial close process.\nAbout SANUWAVE\nSANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.\nSANUWAVE's end-to-end wound care portfolio o...